Ultragenyx Pharmaceutical Inc. (RARE)
PHARMACEUTICAL PREPARATIONS
- Headquarters
- United States
- Employees
- 1,371
- Market Cap
- $2.6B
About Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.
SentiSense also tracks daily options readings for Ultragenyx Pharmaceutical Inc.: IV rank, put/call percentile, 25-delta skew, open-interest walls, and unusually active contracts, each measured against the stock's own history. Sign in to view them.
Ultragenyx Pharmaceutical Inc. stock analysis, sentiment tracking, and market intelligence on SentiSense.